Singular Genomics Systems Stock Forecast, Price & News

Singular Genomics Systems (NASDAQ:OMIC) Frequently Asked Questions

Is Singular Genomics Systems a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Singular Genomics Systems in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Singular Genomics Systems stock.
View analyst ratings for Singular Genomics Systems or view top-rated stocks.

What stocks does MarketBeat like better than Singular Genomics Systems?

Wall Street analysts have given Singular Genomics Systems a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Singular Genomics Systems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Singular Genomics Systems' next earnings date?

Singular Genomics Systems is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Singular Genomics Systems.

How were Singular Genomics Systems' earnings last quarter?

Singular Genomics Systems, Inc. (NASDAQ:OMIC) announced its earnings results on Tuesday, August, 3rd. The company reported ($0.43) EPS for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.22.
View Singular Genomics Systems' earnings history.

What price target have analysts set for OMIC?

4 brokers have issued twelve-month target prices for Singular Genomics Systems' shares. Their forecasts range from $26.00 to $35.00. On average, they expect Singular Genomics Systems' share price to reach $30.33 in the next twelve months. This suggests a possible upside of 156.8% from the stock's current price.
View analysts' price targets for Singular Genomics Systems or view top-rated stocks among Wall Street analysts.

Who are Singular Genomics Systems' key executives?

Singular Genomics Systems' management team includes the following people:

• Mr. Andrew Spaventa, Founder, CEO & Chairperson of the Board (Age 36)
• Mr. David J. Daly, Pres & COO (Age 59)
• Dr. Eli N. Glezer Ph.D., Founder & Chief Scientific Officer (Age 52)
• Mr. Dalen Meeter, Sr. VP of Fin. (Age 43)
• Ms. Daralyn Durie, Gen. Counsel (Age 53)
• Mr. Jorge Velarde Jr., Sr. VP of Corp. Devel. & Strategy (Age 54)
• Mr. Scott Thomas, Sr. VP of Sales & Marketing
• Mr. Vincent Brancaccio, Head of HR (Age 38)

Who are some of Singular Genomics Systems' key competitors?

Some companies that are related to Singular Genomics Systems include Cytek BioSciences (CTKB), HORIBA (HRIBF), Olink Holding AB (publ) (OLK), Quanterix (QTRX), Bionano Genomics (BNGO), Berkeley Lights (BLI), Rapid Micro Biosystems (RPID), Akoya Biosciences (AKYA), Fluidigm (FLDM), EyePoint Pharmaceuticals (EYPT), Accelerate Diagnostics (AXDX), Codex DNA (DNAY), Harvard Bioscience (HBIO), Talis Biomedical (TLIS) and Precipio (PRPO).
View all of OMIC's competitors.

When did Singular Genomics Systems IPO?

(OMIC) raised $178 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank served as the underwriters for the IPO.

What is Singular Genomics Systems' stock symbol?

Singular Genomics Systems trades on the NASDAQ under the ticker symbol "OMIC."

When does the company's lock-up period expire?

Singular Genomics Systems' lock-up period expires on Tuesday, November 23rd. Singular Genomics Systems had issued 10,200,000 shares in its public offering on May 27th. The total size of the offering was $224,400,000 based on an initial share price of $22.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Who are Singular Genomics Systems' major shareholders?

Singular Genomics Systems' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (4.31%), Perceptive Advisors LLC (4.31%), FMR LLC (2.96%), Coatue Management LLC (2.96%), Goldman Sachs Group Inc. (1.37%) and Vanguard Group Inc. (1.06%). Company insiders that own Singular Genomics Systems stock include James E Flynn and Sheryl L Conley.

Which major investors are buying Singular Genomics Systems stock?

OMIC stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, FMR LLC, Coatue Management LLC, Goldman Sachs Group Inc., Vanguard Group Inc., Nicholas Investment Partners LP, and UBS Asset Management Americas Inc..

How do I buy shares of Singular Genomics Systems?

Shares of OMIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Singular Genomics Systems' stock price today?

One share of OMIC stock can currently be purchased for approximately $11.81.

How much money does Singular Genomics Systems make?

Singular Genomics Systems has a market capitalization of $845.08 million.

How many employees does Singular Genomics Systems have?

Singular Genomics Systems employs 138 workers across the globe.

What is Singular Genomics Systems' official website?

The official website for Singular Genomics Systems is singulargenomics.com.

Where are Singular Genomics Systems' headquarters?

Singular Genomics Systems is headquartered at 10931 N. TORREY PINES ROAD SUITE 100, LA JOLLA CA, 92037.

How can I contact Singular Genomics Systems?

Singular Genomics Systems' mailing address is 10931 N. TORREY PINES ROAD SUITE 100, LA JOLLA CA, 92037. The company can be reached via phone at 858-333-7830.